托珠单抗联合甲氨蝶呤治疗难治性类风湿关节炎的疗效观察

发布时间：2018-11-21 20:35

【摘要】：目的·探讨托珠单抗联合甲氨蝶呤治疗难治性中重度活动的类风湿关节炎(RA)的有效性及安全性。方法·10例难治性活动性RA患者接受足量托珠单抗注射液联合甲氨蝶呤口服治疗,观察治疗前(基线)及治疗第12、24周时压痛关节数、肿胀关节数、红细胞沉降率(ESR)、C反应蛋白(CRP)及疾病活动指数28(DAS28)、简化疾病活动指数(SDAI)和临床疾病活动指数(CDAI)等指标的变化,记录不良反应发生情况。结果·与治疗前比较,治疗后第12周和第24周RA患者的关节症状、体征、ESR及DAS28、CDAI、SDAI等指标均有不同程度改善,差异均有统计学意义(P0.05)。无白细胞减少、心功能不全及严重感染等不良反应发生。结论·托珠单抗能快速并显著地改善难治性活动性RA患者的临床症状、体征、活动性指标及关节炎评分。
[Abstract]:Objective to investigate the efficacy and safety of Todzumab combined with methotrexate in the treatment of refractory moderate and severe active rheumatoid arthritis (RA). Methods Ten patients with refractory active RA were treated with adequate tubeumab injection combined with methotrexate orally. The number of tenderness joints, the number of swollen joints and erythrocyte sedimentation rate (ESR),) were observed before treatment (baseline) and 24 weeks after treatment. C-reactive protein (CRP), disease activity index (DAS28), simplified disease activity index (SDAI) and clinical disease activity index (CDAI) were recorded. Results compared with before treatment, the joint symptoms, signs, ESR and DAS28,CDAI,SDAI of RA patients were improved in different degree after 12 weeks and 24 weeks of treatment, and the differences were statistically significant (P0.05). No leukopenia, cardiac insufficiency and severe infection occurred. Conclusion Torzumab can improve the clinical symptoms, signs, activity indexes and arthritis score of refractory active RA patients quickly and significantly.
【作者单位】：上海交通大学医学院附属仁济医院南院风湿科;
【分类号】：R593.22

【相似文献】